The results bring Eli Lilly’s pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight loss and diabetes market.
Related Posts
Baird upgrades Bank of America, as this week’s sell-off is a buying opportunity
The recent pullback in Bank of America is an opportunity for investors to buy the stock, according to Baird.
Ontario to remove U.S. alcohol from shelves after Trump’s tariffs announcement
The Liquor Control Board of Ontario will remove American alcohol from its shelves in response to U.S. President Trump’s tariffs on Canada.
New Boeing CEO to give clues on company’s future, while striking workers vote on new contract
Boeing’s CEO Kelly Ortberg faces investors for first time at the helm of the troubled manufacturer.